The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug is to be ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...